Internal Fractures Emerge Within Kennedy's Health Initiative

Fri Nov 21 2025 15:39:59 GMT+0200 (Eastern European Standard Time)

Robert F. Kennedy Jr. faces criticism from within his 'Make America Healthy Again' movement as supporters express discontent over perceived compromises with pharmaceutical companies and the direction of the initiative.

At a recent 'Make America Healthy Again' event in Washington, Robert F. Kennedy Jr. received high praise from various figures, but backlash ensued as some former supporters accused Trump administration officials of undermining the movement. As tensions rise regarding collaboration with big corporations, internal dissent threatens the unity of Kennedy's broad coalition. While Kennedy asserts the movement's strength and ongoing commitment to public health, critics worry about its evolving agenda and relationships with the pharmaceutical sector.

In a recent event in Washington, Robert F. Kennedy Jr., the Health Secretary, was celebrated at the 'Make America Healthy Again' (MAHA) initiative. Despite the applause, discontent brewed online as former advocates criticized the program's perceived shift in focus.

Gray Delany, a former official ousted in August, voiced concerns over the movement's integrity, claiming, MAHA is not MAHA anymore. This reflection illustrated fractures within Kennedy's coalition, highlighting a growing rift between old supporters and new partnership strategies that include pharmaceutical companies.

Critics particularly pointed to a lack of adequate action on key health priorities, indicating a mistrust of collaborations with large corporations. While MAHA has gained public support with two-thirds of Americans favoring the initiative according to recent polls, the discontent among its core advocates could threaten its longevity.

Kennedy's defensive response to internal grievances showcases the delicate balance he must maintain, navigating the multifaceted interests of diverse stakeholders ranging from health advocates to corporate partners. As votes and public preferences sway, the direction of MAHA and its integrity continues to evolve in a complex landscape of health policy.

With skepticism over vaccine policies and a call for more stringent measures against pharmaceutical missteps, the movement is at a crossroad. Kennedy's next steps will determine not only the future of MAHA but also its foundational principles that have drawn a significant following.